
Genetic information submitted by millions of 23andMe users is now in the hands of pharmaceutical giant Regeneron, following a £200 million acquisition deal.
Originally provided by customers seeking personal health or ancestry insights, the data may now be used to develop new drugs — with limited control or consent from the individuals it came from.